US uses development model to underline devices/pharmaceutical differences
This article was originally published in Clinica
AdvaMed's board of directors has decided to set up a working group that will develop a model of the entire product life cycle of a medical device. Creating a Medical Devices Development Model would give the association a useful tool in illustrating the differences between devices and pharmaceutical drugs, the association believes.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.